Heron Therapeutics, Inc. (HRTX) SEC Filing 8-K Material Event for the period ending Thursday, October 3, 2019

Heron Therapeutics, Inc.

CIK: 818033 Ticker: HRTX

View differences made from one to another to evaluate Heron Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Heron Therapeutics, Inc..


Assess how Heron Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Heron Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Heron Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: HRTX
CIK: 818033
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-264451
Submitted to the SEC: Tue Oct 08 2019 4:01:44 PM EST
Accepted by the SEC: Tue Oct 08 2019
Period: Thursday, October 3, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: